PE20091313A1 - (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina - Google Patents

(r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina

Info

Publication number
PE20091313A1
PE20091313A1 PE2009000004A PE2009000004A PE20091313A1 PE 20091313 A1 PE20091313 A1 PE 20091313A1 PE 2009000004 A PE2009000004 A PE 2009000004A PE 2009000004 A PE2009000004 A PE 2009000004A PE 20091313 A1 PE20091313 A1 PE 20091313A1
Authority
PE
Peru
Prior art keywords
pirazin
tetrahydropyran
phenyl
crystalline
cyclopropansulfonil
Prior art date
Application number
PE2009000004A
Other languages
English (en)
Inventor
Jeanette Tower Dunlap
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091313(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20091313A1 publication Critical patent/PE20091313A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO CRISTALINO DE R-2-(4-CICLOPROANSULFONIL-FENIL)-N-PIRAZIN-2-IL-3-(TETRAHIDROPIRAN-4-IL)-PROPANAMIDA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS X SE OBTIENE DE UNA FUENTE CuKALFA(LAMBDA=1.54056AMSTRONG), EL CUAL COMPRENDE PICOS A: 11.5 Y 19.0 +/- 0.1 EN 2 THETA. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE ADEMAS UN AGENTE DIABETICO O AGENTE ANTIHIPERGLICEMICO. DICHO COMPUESTO ES ACTIVADOR DE GLUCOCINASA UTIL EN LA PREVENCION Y TRATAMIENTO DE HIPERGLICEMIA
PE2009000004A 2008-01-15 2009-01-05 (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina PE20091313A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2113308P 2008-01-15 2008-01-15

Publications (1)

Publication Number Publication Date
PE20091313A1 true PE20091313A1 (es) 2009-09-03

Family

ID=40451065

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000004A PE20091313A1 (es) 2008-01-15 2009-01-05 (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina

Country Status (22)

Country Link
US (1) US20090181981A1 (es)
EP (1) EP2265271A1 (es)
JP (1) JP2011509934A (es)
KR (1) KR20100092061A (es)
CN (1) CN101909629A (es)
AR (1) AR070107A1 (es)
AU (1) AU2009205606A1 (es)
BR (1) BRPI0907165A2 (es)
CA (1) CA2712245A1 (es)
CL (1) CL2009000004A1 (es)
CO (1) CO6280489A2 (es)
DO (1) DOP2010000216A (es)
EA (1) EA201070853A1 (es)
EC (1) ECSP10010347A (es)
IL (1) IL206102A0 (es)
MA (1) MA31985B1 (es)
MX (1) MX2010007784A (es)
PE (1) PE20091313A1 (es)
TN (1) TN2010000299A1 (es)
TW (1) TW200934772A (es)
WO (1) WO2009091634A1 (es)
ZA (1) ZA201003909B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016687B8 (ru) 2007-08-22 2012-07-30 Астразенека Аб Производные циклопропиламида
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
SG183231A1 (en) * 2010-02-18 2012-09-27 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
KR20130004296A (ko) * 2010-02-18 2013-01-09 아스트라제네카 아베 시클로프로필 아미드 유도체의 제조 방법 및 그와 관련된 중간체
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101220371B1 (ko) 2010-09-17 2013-01-09 현대자동차주식회사 베인펌프
EP2674517B1 (en) * 2011-02-08 2018-10-03 Japan Agency for Marine-Earth Science and Technology Method for producing calcite single crystal
JP2013014534A (ja) * 2011-07-04 2013-01-24 Daicel Corp ベンゾイルギ酸化合物、及びその製造方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046768A (en) * 1976-06-17 1977-09-06 Velsicol Chemical Corporation 1-Thiazolyl-5-pyridylcarbonyloxyimidazolidinones
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
EP1282612B1 (en) * 2000-05-03 2004-12-29 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
JP3839723B2 (ja) * 2000-05-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 置換フェニルアセトアミドおよびグルコキナーゼ活性化剤としてのその使用
US6489485B2 (en) * 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
JP4138478B2 (ja) * 2000-07-20 2008-08-27 エフ．ホフマン−ラ ロシュ アーゲー アルファ−アシル及びアルファ−ヘテロ原子置換ベンゼンアセトアミドのグルコキナーゼアクチベーター
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
KR100545431B1 (ko) * 2000-12-06 2006-01-24 에프. 호프만-라 로슈 아게 축합된 이종방향족 글루코키나제 활성화제
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
US6911545B2 (en) * 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
KR20060134179A (ko) * 2004-04-21 2006-12-27 프로시디온 리미티드 트리(사이클로) 치환된 아미드 화합물
KR20080105180A (ko) * 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
GB0418058D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
AU2006310474A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
CA2628486A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd. Tricyclo substituted amides
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators

Also Published As

Publication number Publication date
KR20100092061A (ko) 2010-08-19
DOP2010000216A (es) 2010-10-15
TN2010000299A1 (en) 2011-11-11
US20090181981A1 (en) 2009-07-16
CA2712245A1 (en) 2009-07-23
MA31985B1 (fr) 2011-01-03
BRPI0907165A2 (pt) 2015-07-14
AR070107A1 (es) 2010-03-17
JP2011509934A (ja) 2011-03-31
CL2009000004A1 (es) 2010-02-19
CO6280489A2 (es) 2011-05-20
WO2009091634A1 (en) 2009-07-23
ZA201003909B (en) 2011-11-30
EA201070853A1 (ru) 2010-12-30
IL206102A0 (en) 2010-11-30
TW200934772A (en) 2009-08-16
MX2010007784A (es) 2010-08-09
ECSP10010347A (es) 2010-09-30
EP2265271A1 (en) 2010-12-29
CN101909629A (zh) 2010-12-08
AU2009205606A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
PE20091313A1 (es) (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
WO2006119283A3 (en) Anti-odor compositions and therapeutic use
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
EP2070509A3 (en) The use of Myrica gale oil
CR11441A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
ECSP10010160A (es) Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
PE20110019A1 (es) Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina
CL2008000133A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
RS53056B (en) PHARMACEUTICAL PREPARATION CONTAINING (1S) -1,5-ANHYDRO-1- [5- (4-ETHOXYBENZYL) -2-METHOXY-4-METHYLPHENYL] -1-THI-D-GLUCITOL AND METFORMIN AND ITS USE IN THE TREATMENT OF DIABETES
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
PE20081350A1 (es) Sal fumarato de (alfas s, beta r)-6-bromo-alfa-[2(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
CL2007001597A1 (es) Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
BRPI0514250A (pt) uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
UA109627C2 (uk) Композиції тетрациклінових сполук для орального введення та ін'єкцій
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica

Legal Events

Date Code Title Description
FD Application declared void or lapsed